Evidence mapPaperPMID 42521410Full record

ArticleJournal for immunotherapy of cancer2026

Adipocyte-derived LTB4 programs human NKG2A

Xiaoxiao Hu, Dang Wu, Fang Jia, Sangsang Zhu, Shouyu Ke, Di Chen, Jing Zhao, Lili Li, Yi Zhang, Zhen Wang and 24 more

Abstract read
In one paragraph

Article in Journal for immunotherapy of cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

34 authors.

Xiaoxiao Hu *Department of Breast Surgery, The Second Affiliated Hospital Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
Dang Wu *Key Laboratory of Tumor Microenvironment and Immune Therapy of Zhejiang Province, The Second Affiliated Hospital Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
Fang Jia *Department of Breast Surgery, The Second Affiliated Hospital Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
Sangsang ZhuKey Laboratory of Tumor Microenvironment and Immune Therapy of Zhejiang Province, The Second Affiliated Hospital Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
Shouyu KeDepartment of Breast Surgery, The Second Affiliated Hospital Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
Di ChenDepartment of Breast Surgery, The Second Affiliated Hospital Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
Jing ZhaoKey Laboratory of Tumor Microenvironment and Immune Therapy of Zhejiang Province, The Second Affiliated Hospital Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
Lili LiKey Laboratory of Tumor Microenvironment and Immune Therapy of Zhejiang Province, The Second Affiliated Hospital Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
Yi ZhangDepartment of Breast Surgery, The Second Affiliated Hospital Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
Zhen WangDepartment of Breast Surgery, The Second Affiliated Hospital Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
Xiaoyan JinDepartment of Surgical Oncology, Taizhou Municipal Hospital, Taizhou, Zhejiang, China.ORCID http://orcid.org/0000-0001-8454-6710
Wangyu ZhuKey Laboratory of Tumor Microenvironment and Immune Therapy of Zhejiang Province, The Second Affiliated Hospital Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
Fengbo HuangDepartment of Pathology, The Second Affiliated Hospital Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
Hailang ChenDepartment of Oncology, Lanxi People's Hospital, Jinhua, Zhejiang, China.
Ping XingDepartment of Breast Surgery, The Second Affiliated Hospital Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
Jinhua DingDepartment of Breast Surgery, Ningbo Medical Centre Lihuili Hospital, Ningbo, Zhejiang, China.
Liwei MengDepartment of General Surgery (Breast and Thyroid Surgery), Shaoxing People's Hospital, Shaoxing, Zhejiang, China.
Yunfeng DingDepartment of Breast Surgery, Huzhou Central Hospital, Huzhou, Zhejiang, China.
Yongpan WangThe First People's Hospital of Jiashan, Jiaxing, Zhejiang, China.
Jing XuDepartment of Breast Surgery, Zhejiang University Zhoushan Hospital, Zhoushan, Zhejiang, China.
Guohong RenDepartment of Breast Surgery, The Second Affiliated Hospital Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
Wuzhen ChenDepartment of Breast Surgery, The Second Affiliated Hospital Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
Xuan ShaoDepartment of Breast Surgery, The Second Affiliated Hospital Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
Chao NiDepartment of Breast Surgery, The Second Affiliated Hospital Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
Xiuyan YuDepartment of Breast Surgery, The Second Affiliated Hospital Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
Liwei PangDepartment of Breast Surgery, The Second Affiliated Hospital Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
Leyi ZhangDepartment of Breast Surgery, The Second Affiliated Hospital Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
Jun PanDepartment of Breast Surgery, The Second Affiliated Hospital Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
Weiwei PanDepartment of Breast Surgery, The Second Affiliated Hospital Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
Ningning XuKey Laboratory of Tumor Microenvironment and Immune Therapy of Zhejiang Province, The Second Affiliated Hospital Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
Zhuohang YuKey Laboratory of Tumor Microenvironment and Immune Therapy of Zhejiang Province, The Second Affiliated Hospital Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
Fuming QiuKey Laboratory of Tumor Microenvironment and Immune Therapy of Zhejiang Province, The Second Affiliated Hospital Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
Jun YanDivision of Immunotherapy, Department of Surgery, Immuno-Oncology Program, James Graham Brown Cancer Center, Louisville, Kentucky, USA drhuangjian@zju.edu.cn jun.yan@louisville.edu.ORCID http://orcid.org/0000-0003-2922-422X
Jian HuangDepartment of Breast Surgery, The Second Affiliated Hospital Zhejiang University School of Medicine, Hangzhou, Zhejiang, China drhuangjian@zju.edu.cn jun.yan@louisville.edu.ORCID http://orcid.org/0000-0003-3340-5007

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe peritumoral microenvironment has emerged as a key role in affecting tumor invasion and immunotherapy responses. In adipose-enriched tumors, such as breast cancer (BC), peritumoral adipose tissue (PA) harbors unconventional immune populations, yet its immunological functions remain poorly understood. In particular, how adipocyte regulate innate-like lymphocytes, such as γδ T cells, remains unclear.

methodsWe performed single-cell RNA sequencing and spatial profiling of paired specimens from patients with BC. Integrated multi-omics analyses, immunofluorescence staining, human γδ T-cell expansion assays, functional assays, and in vivo models were used to define the immune cell states and evaluate the impact of lipid mediator leukotriene B4 (LTB4) on γδ T-cell activation and signaling. Clinical correlations were assessed using our cohort and patient datasets.

resultsWe identified a previously unrecognized population of NKG2A

conclusionsThese findings redefine PA as an active immunological niche that programs γδ T-cell immunity through adipocyte-derived LTB4 signaling. Our study identifies NKG2A

Indexed as

AdipocytesAdipose TissueBreast NeoplasmsLeukotriene B4Receptors, Antigen, T-Cell, gamma-deltaAnimalsFemaleHumansMiceTumor MicroenvironmentLeukotriene B4Receptors, Antigen, T-Cell, gamma-deltaBreast CancerInnateT cellTumor microenvironment - TME

Identifiers

PMID42521410
PMCPMC13422814

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.